Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o.
- Address
- lock Available on a paid plan
Alergo-Med Specialized Allergy and Respiratory Research Center
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o. is a distinguished clinical research facility specializing in allergic and respiratory conditions. The center has established particular expertise in conducting complex trials for dermatological conditions, with a strong focus on atopic dermatitis across multiple age groups, from infants to adults. Their research portfolio demonstrates proficiency in evaluating novel biologics, immunomodulatory therapies, and allergen-specific immunotherapies.
- Atopic dermatitis treatment development, including biologic agents and advanced immunotherapies for moderate-to-severe disease in pediatric and adult populations
- Allergic rhinitis and rhinoconjunctivitis research, particularly seasonal allergies induced by birch and other pollens, with emphasis on allergen immunotherapy trials
- Asthma management studies spanning pediatric to adult populations, including evaluation of bronchodilators, anti-inflammatory agents, and novel biologics for uncontrolled disease
- Respiratory infectious diseases and recurrent wheezing conditions in children, including RSV infection treatment protocols
The research center demonstrates comprehensive capabilities in managing diverse study designs, from early phase 2 dose-ranging studies to large phase 3 registration trials. Their experience encompasses randomized controlled trials, open-label studies, and long-term safety assessments. The facility's particular strength lies in pediatric allergy and respiratory research, conducting specialized trials in populations ranging from infants as young as 6 months to adolescents and adults, while maintaining expertise in rare conditions such as vitiligo treatment development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 67 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Pfizer Inc.2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 4 | Unknown | 2022-08-29 | 2024-08-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.